Literature DB >> 9329460

Human mucopolysaccharidosis IIID: clinical, biochemical, morphological and immunohistochemical characteristics.

M Z Jones1, J Alroy, J C Rutledge, J W Taylor, E C Alvord, J Toone, D Applegarth, J J Hopwood, E Skutelsky, C Ianelli, D Thorley-Lawson, C Mitchell-Herpolsheimer, A Arias, P Sharp, W Evans, D Sillence, K T Cavanagh.   

Abstract

Mucopolysaccharidosis IIID (MPS IIID) is one of the rarest of the MPS-III syndromes. To date, the clinical manifestations of 10 patients have been reported, the deficient N-acetylglucosamine 6-sulfatase (G6S) enzyme has been purified, and the G6S gene has been cloned, sequenced and localized. However, morphological manifestations of this condition have not been reported and the pathogenesis of the severe neurological deficits remains an enigma. In this paper we describe and correlate the clinical, biochemical and pathological observations for 2 cases of MPS IIID. We used monoclonal antibodies against heparan sulfate (HS) and GM2-ganglioside, thin layer chromatography, mass spectrometry, and morphological techniques to demonstrate the nature and the distribution of the uncatabolized substrates. The majority of the cells in various tissues showed morphological changes expected with lysosomal storage of HS. The central nervous system (CNS) was most severely affected because of the secondary storage of GM2 and GM3 gangliosides in addition to the primary accumulation of HS. The extent as well as the distribution of the diverse storage materials varied within and among different neurons as observed in MPS-III A, B, and C syndromes. This study supports the hypothesis that the neurological dysfunction and neurodegeneration common to the Sanfilippo syndromes is, in part, due to the secondary metabolic perturbations induced by HS accumulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9329460

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  21 in total

1.  Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy.

Authors:  E Downs-Kelly; M Z Jones; J Alroy; K T Cavanagh; B King; R E Lucas; J C Baker; S A Kraemer; J J Hopwood
Journal:  J Mol Neurosci       Date:  2000-12       Impact factor: 3.444

Review 2.  Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.

Authors:  Dao Pan
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

3.  Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase.

Authors:  H H Li; W H Yu; N Rozengurt; H Z Zhao; K M Lyons; S Anagnostaras; M S Fanselow; K Suzuki; M T Vanier; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

4.  Epidemiology of mucopolysaccharidoses.

Authors:  Shaukat A Khan; Hira Peracha; Diana Ballhausen; Alfred Wiesbauer; Marianne Rohrbach; Matthias Gautschi; Robert W Mason; Roberto Giugliani; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-05-26       Impact factor: 4.797

5.  Ataxia is the major neuropathological finding in arylsulfatase G-deficient mice: similarities and dissimilarities to Sanfilippo disease (mucopolysaccharidosis type III).

Authors:  Björn Kowalewski; Peter Heimann; Theresa Ortkras; Renate Lüllmann-Rauch; Tomo Sawada; Steven U Walkley; Thomas Dierks; Markus Damme
Journal:  Hum Mol Genet       Date:  2014-12-01       Impact factor: 6.150

6.  Recombinant caprine 3H-[N-acetylglucosamine-6-sulfatase] and human 3H-[N-acetylgalactosamine-4-sulfatase]: plasma clearance, tissue distribution, and cellular uptake in the rat.

Authors:  M Z Jones; L K Brumfield; B M King; J J Hopwood; S Byers
Journal:  J Mol Neurosci       Date:  1998-12       Impact factor: 3.444

7.  Mucolipidosis type III α/β: the first characterization of this rare disease by autopsy.

Authors:  Darcy A Kerr; Vincent A Memoli; Sara S Cathey; Brent T Harris
Journal:  Arch Pathol Lab Med       Date:  2011-04       Impact factor: 5.534

8.  A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs.

Authors:  N M Ellinwood; P Wang; T Skeen; N J H Sharp; M Cesta; S Decker; N J Edwards; I Bublot; J N Thompson; W Bush; E Hardam; M E Haskins; U Giger
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

9.  Caprine mucopolysaccharidosis IIID: fetal and neonatal brain and liver glycosaminoglycan and morphological perturbations.

Authors:  Margaret Z Jones; Joseph Alroy; Erinn Downs-Kelly; Rebecca E Lucas; Stacey A Kraemer; Kevin T Cavanagh; Barbara King; John J Hopwood
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 10.  Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed.

Authors:  S Al Sawaf; E Mayatepek; B Hoffmann
Journal:  J Inherit Metab Dis       Date:  2008-07-13       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.